Brain Tumor MSK 17-261

The purpose of this study is to assess the safety and effectiveness of the drug abemaciclib in patients with brain tumors that have come back despite prior radiation therapy and/or chemotherapy. The study will include patients with glioma, meningioma, ependymoma, primary central nervous system lymphoma, and other brain tumor types.

Abemaciclib is designed to inhibit cancer growth by blocking cyclin-dependent kinases (CDK), enzymes which cancer cells need to grow and divide. It is approved for treating metastatic breast cancer; its use in this study is investigational (Clinical trials test how well investigational drugs work and whether they are safe to use). It is taken orally (by mouth).

Eligibility Criteria

Patients must have a brain tumor that has come back or continued to grow despite prior treatment. Patients must also have recovered from the serious side effects of prior therapies before entering the study.

This study is for patients age 18 and older.

Available at: Hartford Hospital, the Hospital of Central Connecticut, MidState Medical Center

Cancer Clinical Research Office